Biointron’s Q2 2026 Antibody Industry Trends report aims to explore the events and trends of the biopharmaceutical industry in April, May, and June. This quarter, six novel monoclonal antibody drugs have received first approval.
Seasonal influenza causes an estimated one billion infections, 3-5 million severe cases, and 300,000-500,000 deaths globally each year. According to a recent review, existing vaccines provide variable protection because their effectiveness depends on how closely vaccine strains match circulating viruses. Influenza also evolves through antigenic drift and, less frequently, antigenic shift, while resistance can reduce the effectiveness of antiviral drugs.
Artificial intelligence can now help researchers analyze antibody sequences, predict structures, prioritize mutations, optimize candidate properties, and generate entirely new antibody sequences. These capabilities are changing what can be proposed computationally, but every proposed sequence raises the practical question: will the antibody actually work?
Time: April 15 - 19, 2026
Location: Boston, MA
Booth: #1228
Time: April 28 – 30, 2026
Location: Seoul, South Korea
Booth: #B31
Time: May 9 - 10, 2026
Location: Boston, MA
The antibody therapeutics sector is rapidly evolving, transitioning from traditional hybridoma methods to single B and AI-driven de novo design approaches, significantly compressing discovery timelines and creating novel binding moieties.
Biointron’s 2026 Lunch & Learn, held at CIC Cambridge on May 8, 2026, featured expert presentations from SeromYx Systems and Visterra on two critical areas of antibody and biologic development: Fc-effector function profiling and cell-based neutralizing antibody (NAB) assay design.
This webinar provides an overview of Antibody-Drug Conjugates (ADCs) and expanded drug conjugates (XDCs), with a focus on Biointron's experiences and capabilities.
When you’re a small biotech with big ambitions, every week counts. For Macomics Limited, that meant finding a way to get high-quality antibodies quick···
The demand for fully human therapeutic antibodies continues to grow, driving the need for more efficient discovery platforms.
Case 1: Tag-Free Vaccine Protein. During the generation of stable cell lines, cells are selected and screened to identify clones that stably express t···
Apply for Biointron's Quarterly Travel Grant. Receive $800 to support early-career antibody researchers in attending scientific conferences, symposia, and workshops.
Submit a quick Biointron testimonial and we’ll send you a $25 Amazon gift card. Simple, fast, and appreciated!
Get 25% off your next Biointron project when you cite us in your paper!
Spotlight on Antibodies is a podcast from Biointron, where we bring you the latest antibody industry trends. This month in June, we'll highlight the era of AI-driven antibody discovery.
Spotlight on Antibodies is a podcast from Biointron, where we bring you the latest antibody industry trends. This month in May, we'll highlight the future of VHH technology, chemical conjugation in antibody therapeutics, and emerging trends in antibody characterization.
Spotlight on Antibodies is a podcast from Biointron, where we bring you the latest antibody industry trends. This month in April, we'll highlight ATP-dependent switch antibodies, the throughput-quality gap in antibody discovery, and multiple myeloma antibody treatments.
Two popular topics discussed at the 2026 BIO International Convention were developments in antibody-drug conjugates (ADCs) and AI in biology. Held on June 22-25 in San Diego, California, read on for a quick recap.
AI is changing antibody discovery, but model performance depends on the quality of the experimental data used to train, validate, and refine predictions. Antibody researchers increasingly need more structured, comparable, and biologically meaningful datasets that link sequence design to expression, binding, and developability outcomes.
Antibody discovery has become increasingly sequence-rich. Display technologies, single B cell workflows, computational design, and AI-enabled antibody engineering can now generate large numbers of candidate sequences for evaluation. However, a larger sequence pool does not automatically translate into better lead candidates.
You can also contact us on the Scientist and Science Exchange marketplaces.
